Prosecution Insights
Last updated: July 17, 2026
Application No. 18/273,678

COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY

Final Rejection §102
Filed
Jul 21, 2023
Priority
Jan 22, 2021 — provisional 63/140,533 +1 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cornell University
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1217 granted / 1629 resolved
+14.7% vs TC avg
Strong +16% interview lift
Without
With
+15.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
46 currently pending
Career history
1664
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
9.8%
-30.2% vs TC avg
§102
12.5%
-27.5% vs TC avg
§112
49.8%
+9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1629 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-3, 5-9, 11-15 and 17-21 are pending in the application. This action is in response to applicants' amendment dated March 6, 2026. Claims 1, 6, 13-15, 17 and 19-21 have been amended and claims 10 and 22 have been canceled. Response to Amendment Applicant's arguments filed March 6, 2026 have been fully considered with the following effect: The applicants’ amendments are sufficient to overcome the 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph rejection, labeled paragraph 1) in the last office action, which is hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 2a) and b) in the last office action, which are hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 102(a)(1), anticipation rejection, labeled paragraph 3) in the last office action, which is hereby withdrawn. With regards to the 35 U.S.C. 102(a)(1), anticipation rejection, labeled paragraph 4) in the last office action, the applicant's arguments have been fully considered, however they were not found persuasive. The applicants’ stated that Pan does not qualify as prior art against the instant application. Applicant respectfully submits that Pan is not prior art to the present application because Pan is a non-patent literature with a publication date of November 15, 2021. The instant application is a U.S. National Phase Application Under 35 U.S.C. § 371 of International Application No. PCT/US2022/013276, filed on January 21, 2022, and claims the benefit of and priority to U.S. Provisional Patent Application No. 63/140,533 filed January 22, 2021. Accordingly, Pan fails to qualify as prior art to the instant application because the earliest effective priority date pre-dates publication of the reference. The applicants are reminded that the earliest priority date of the instant application (January 22, 2022; which corresponds to the filing date of PCT/US2022/013276). The applicants are not entitled to benefit of application 63/140,533, which does not provide clear support (description and enablement) of the claimed subject matter. Note for benefit under 35 USC 119, there must be clear support (description and enablement) for claims instantly rejected herein as was set forth in in re Scheiber 199 USPQ 782; In re Lukach, 169 USPQ 795; In re Gostelli, 10 USPQ 2nd 1614; Kawai v. Metlesics 178 USPQ 159. Claim(s) 1-3, 5-9, 11-15 and 17-21 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pan et al., PNAS, for reasons of record and stated above. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 21, 2023
Application Filed
Nov 07, 2025
Non-Final Rejection mailed — §102
Mar 06, 2026
Response Filed
Apr 15, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679850
TYK2 INHIBITORS AND USES THEREOF
3y 4m to grant Granted Jul 14, 2026
Patent 12678443
MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE
2y 2m to grant Granted Jul 14, 2026
Patent 12661343
COMPOSITIONS CONTAINING NICOTINAMIDE AND VITAMIN B6 AND METHODS OF USING SUCH COMPOSITIONS FOR PROMOTING MUSCLE GROWTH
3y 1m to grant Granted Jun 23, 2026
Patent 12655107
OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1)
5y 4m to grant Granted Jun 16, 2026
Patent 12648986
PLD FOR USE IN COMBINATION IN THE TREATMENT OF CORONAVIRUS
3y 9m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.5%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1629 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month